Literature DB >> 1954005

The 1st International Standard for anti-measles serum.

T Forsey1, A B Heath, P D Minor.   

Abstract

The 1st International Standard for anti-measles serum has been established on the basis of a collaborative study. There were four participating laboratories in four countries and three types of assay used. This standard has been assigned a potency of 5 IU anti-measles antibody per ampoule.

Mesh：

Substances：

Year:  1991        PMID： 1954005     DOI： 10.1016/1045-1056(91)90042-i

Source DB:  PubMed          Journal:  Biologicals        ISSN： 1045-1056            Impact factor:   1.856


  11 in total

1.  Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity.

Authors:  F Bouche; W Ammerlaan; F Berthet; S Houard; F Schneider; C P Muller
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

2.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Measles immunity and response to revaccination among secondary school children in Cumbria.

Authors:  N Calvert; F Cutts; R Irving; D Brown; J Marsh; E Miller
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

4.  A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women.

Authors:  R Brugha; M Ramsay; T Forsey; D Brown
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

5.  Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

Authors:  K J Stittelaar; L S Wyatt; R L de Swart; H W Vos; J Groen; G van Amerongen; R S van Binnendijk; S Rozenblatt; B Moss; A D Osterhaus
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak.

Authors:  Ravit Bassal; Victoria Indenbaum; Rakefet Pando; Tal Levin; Eilat Shinar; Doron Amichay; Mira Barak; Anat Ben-Dor; Adina Bar Haim; Ella Mendelson; Dani Cohen; Tamy Shohat
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

7.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

8.  Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Authors:  Bracha Rager-Zisman; Elina Bazarsky; Agneta Skibin; Guy Tam; Shlomo Chamney; Ilana Belmaker; Iris Shai; Ella Kordysh; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody.

Authors:  S Ratnam; V Gadag; R West; J Burris; E Oates; F Stead; N Bouilianne
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

10.  Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK.

Authors:  Anjeanette Roberts; John Wood; Kanta Subbarao; Morag Ferguson; David Wood; Thomas Cherian
Journal:  Vaccine       Date:  2006-07-18       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.